Analyses of the FLAURA and AURA3 trials presented at the ESMO 2018 Congress in Munich, Germany, shed light on the genetic mechanisms of acquired resistance to the third generation EGFR–tyrosine kinase inhibitor osimertinib.
The ALESIA trial comprising treatment-naïve patients with advanced anaplastic lymphoma kinase translocation-positive non-small-cell lung cancer confirms the systemic and intracranial efficacy of alectinib over crizotinib in an Asian population.
The CTONG-1103 EMERGING trial investigators believe that neoadjuvant treatment with epidermal growth factor receptor–tyrosine kinase inhibitors for stage IIIA-N2 non-small-cell lung cancer warrants further investigation.
Combining the highly selective MET inhibitor tepotinib with gefitinib could benefit patients with non-small-cell lung cancer that has progressed on first-line treatment with an EGFR–tyrosine kinase inhibitor and has high levels of MET, suggest phase II trial results.
Vassiliki Papadimitrakopoulou outlines the candidate molecular mechanisms of acquired osimertinib resistance as revealed in the AURA3 trial and discusses the possibilities for later lines of treatment (4:12).